Strategic partnerships Devyser has a track record of collaborations with major players like Illumina and Thermo Fisher Scientific, and recent partnerships such as Pirche AG. These relationships indicate a strong channel strategy and potential for co-development or distribution agreements to expand market reach in oncology, hereditary diseases, and transplantation diagnostics.

Expansion signals Frequent press coverage of product launches and study publications, including dd-cfDNA detection in kidney transplants and new products like LynchFAP and BRCA PALB2, suggests ongoing product modernization and an opportunity to upsell adjacent assay panels, companion diagnostics, or expanded indications to existing customers.

Global adoption With routine diagnostic laboratories in more than 60 countries already using Devyser products, the company demonstrates scalable adoption. This supports a sales approach emphasizing international deployment, standardized quality (ISO 13485), and regional regulatory considerations to win new labs and expand into underserved geographies.

Clinical utility Focused on complex DNA testing for oncology, hereditary diseases, and transplantation, Devyser products target high-need clinical use cases where precise variant detection reduces diagnostic uncertainty. This presents opportunities for value-based selling around treatment guidance, prenatal diagnostics speed, and post-transplant monitoring.

Technology leadership Investment in long-range PCR and advanced dd-fDNA assays positions Devyser as a technically innovative supplier. Sales conversations can highlight differentiation through reproducibility, reduced user error, ISO 13485 compliance, and a robust roadmap for future diagnostics development.